Shares of Neoleukin Therapeutics, Inc. (NASDAQ:NLTX - Get Free Report) rose 8.3% on Thursday . The stock traded as high as $10.71 and last traded at $10.46. Approximately 391,066 shares were traded during mid-day trading, an increase of 681% from the average daily volume of 50,104 shares. The stock had previously closed at $9.66.
Neoleukin Therapeutics Trading Down 9.1 %
The stock has a market cap of $82.61 million, a P/E ratio of -2.83 and a beta of 1.11. The stock's 50-day moving average is $16.26 and its 200-day moving average is $27.48.
Neoleukin Therapeutics Company Profile
(
Get Free Report)
Neoleukin Therapeutics, Inc, a biopharmaceutical company, develops immunotherapies for cancer, inflammation, and autoimmunity disorders using protein design technology. The company's lead product candidate is NL-201, a de novo protein designed to mimic the therapeutic activity of the cytokines interleukin (IL)-2/IL-15 for the treatment of various types of cancer, including renal cell carcinoma and melanoma.
Read More
Before you consider Neoleukin Therapeutics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Neoleukin Therapeutics wasn't on the list.
While Neoleukin Therapeutics currently has a Hold rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Unlock your free copy of MarketBeat's comprehensive guide to pot stock investing and discover which cannabis companies are poised for growth. Plus, you'll get exclusive access to our daily newsletter with expert stock recommendations from Wall Street's top analysts.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
